Clinical significance of aberrant mammalian target of rapamycin expression in stage IIIB colon cancer

Wen,Meiling; Li,Baoxiu; Cao,Xiaofei; Weng,Chengyin; Wu,Yong; Fang,Xisheng; Zhang,Xiaoshi; Liu,Guolong

doi:10.3892/ol.2014.2285

Clinical significance of aberrant mammalian target of rapamycin expression in stage IIIB colon cancer

Authors:
- Meiling Wen
- Baoxiu Li
- Xiaofei Cao
- Chengyin Weng
- Yong Wu
- Xisheng Fang
- Xiaoshi Zhang
- Guolong Liu
View Affiliations

Affiliations: Department of Medical Oncology, Affiliated Nanhua Hospital, Nan Hua University of South China, Hengyang, Hunan 421002, P.R. China, Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat‑Sen University, Guangzhou, Guangdong 510275, P.R. China
Published online on: June 25, 2014 https://doi.org/10.3892/ol.2014.2285
Pages: 1080-1086

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the significance of aberrant expression of mammalian target of rapamycin (mTOR) and the activated form of mTOR kinase, phosphorylated mTOR (pmTOR), in human stage IIIB colon cancer. The expression of mTOR and pmTOR was detected by immunohistochemistry in the tumor tissue of stage IIIB colon cancer patients. The association between the expression of mTOR, pmTOR and clinicopathological parameters of patients was analyzed. The positive expression of mTOR and pmTOR was observed to be higher in 75.5% (80/106) and 76.4% (81/106) of the 106 colon cancer specimens, compared with the adjacent normal tissues. The high level of pmTOR expression was found to be significantly higher in the invasive tumor front cells and resulted in a higher risk of mortality. The results suggested that mTOR and pmTOR may be promising clinical markers and present novel molecular targets for designing novel therapeutic strategies to treat this malignancy.

View Figures

View References

1	Shike M, Winawer SJ, Greenwald PH, et al: Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ. 68:377–385. 1990.
2	Jonker DJ, Spithoff K and Maroun J; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol). 23:314–322. 2011.
3	Monga DK and O’Connell MJ: Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. Ann Surg Oncol. 13:1021–1034. 2006.
4	Ross JS, Torres-Mora J, Wagle N, et al: Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 134:478–490. 2010.
5	Karar J and Maity A: PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci. 4:512011.
6	Foster DA: Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta. 1791:949–955. 2009.
7	Sheppard KE, Cullinane C, Hannan KM, et al: Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer. 49:3936–3944. 2013.
8	Montané MH and Menand B: ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change. J Exp Bot. 64:4361–4374. 2013.
9	Kim A, Yim NH and Ma JY: Samsoeum, a traditional herbal medicine, elicits apoptotic and autophagic cell death by inhibiting Akt/mTOR and activating the JNK pathway in cancer cells. BMC Complement Altern Med. 13:2332013.
10	Burris HA III: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013.
11	Vicuna B and Benson AB III: Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. J Natl Compr Canc Netw. 5:927–936. 2007.
12	Lenehan PF, Boardman LA, Riegert-Johnson D, et al: Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma. Cancer. 118:5234–5244. 2012.
13	Polak P and Hall MN: mTOR and the control of whole body metabolism. Curr Opin Cell Biol. 21:209–218. 2009.
14	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007.
15	Gough NR: Focus issue: TOR signaling, a tale of two complexes. Sci Signal. 5:eg42012.
16	Dunlop EA and Tee AR: Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal. 21:827–835. 2009.
17	Gulhati P, Cai Q, Li J, et al: Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res. 15:7207–7216. 2009.
18	Zhang YJ, Zhao SL, Tian XQ, et al: Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer. Int J Colorectal Dis. 24:629–639. 2009.
19	McCarty MF: mTORC1 activity as a determinant of cancer risk - rationalizing the cancer-preventive effects of adiponectin, metformin, rapamycin, and low-protein vegan diets. Med Hypotheses. 77:642–648. 2011.
20	Su B and Jacinto E: Mammalian TOR signaling to the AGC kinases. Crit Rev Biochem Mol Biol. 46:527–547. 2011.
21	Jiang H, Shang X, Wu H, et al: Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol. 8:25–33. 2009.
22	Ghayad SE and Cohen PA: Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov. 5:29–57. 2010.
23	LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 11:32–50. 2008.
24	Marinov M, Fischer B and Arcaro A: Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol. 63:172–182. 2007.
25	Georgakis GV and Younes A: From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther. 6:131–140. 2006.
26	Ferrandiz-Pulido C, Masferrer E, Toll A, et al: mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior. J Urol. 190:2288–2295. 2013.
27	Hager M, Haufe H, Lusuardi L, et al: PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. Cancer Invest. 29:427–438. 2011.
28	Choi CH, Lee JS, Kim SR, et al: Clinical significance of pmTOR expression in endometrioid endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 153:207–210. 2010.
29	Tampellini M, Longo M, Cappia S, et al: Co-expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. Virchows Arch. 450:321–328. 2007.
30	Dobashi Y, Suzuki S, Matsubara H, et al: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer. 115:107–118. 2009.
31	Yu G, Wang J, Chen Y, et al: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 15:1821–1829. 2009.